Human Metapneumovirus (hMPV) Rapid Test Product Guide – Distributor Edition TL;DR hMPV is surging — the 2024 China outbreak showed hMPV linked to 6.2% of positive respiratory tests, surpassing COVID-19 and adenovirus in the same period. No vaccine, no antiviral — because hMPV has no approved treatment or vaccine, testing is the primary clinical tool for patient management and infection control. Multiplex combo tests are the future — our TGA-approved 6-in-1 cassette detects Flu A/B, COVID-19, hMPV, RSV, and adenovirus from a single nasal swab in 15 minutes. Distributors who add hMPV to their respiratory portfolio now will capture demand before the next winter respiratory season peaks. Our Testsealabs production team manufactures hMPV rapid antigen tests and multiplex combo panels under Australian TGA certification, with a minimum order of 5,000 units and 24-month shelf life. Table of Contents hMPV Is Rising: Why This Respiratory Virus Demands Attention in 2025-2026 What Is hMPV? A Virus Hiding in Plain Sight Since 2001 Clinical Impact: Who Gets Sick and How Bad Why hMPV Matters for Distributors: Market Demand Beyond Flu and COVID Testing hMPV: From Molecular Assays to Rapid Antigen Tests Multiplex Combo Tests: The Future of Respiratory Diagnostics What Distributors Need to Know: Regulatory, Storage, and MOQ How Testsealabs Supports Your hMPV Test Portfolio Frequently Asked Questions 1. hMPV Is Rising: Why This Respiratory Virus Demands Attention in 2025-2026 In our ongoing work supplying respiratory infectious disease rapid test kits to distributors across 100+ countries, we have carefully watched a clear trend emerge: human metapneumovirus (hMPV) is no longer a niche diagnostic concern. It is becoming a mainstream respiratory pathogen that our distributors must address in their product portfolios. We noticed the signal was unmistakable in December 2024, when China’s Center for Disease Control and Prevention published surveillance data showing hMPV was linked to 6.2% of positive respiratory illness tests and 5.4% of respiratory-illness hospitalizations during the week of December 16-22, 2024. In our analysis, those numbers placed hMPV ahead of COVID-19, rhinovirus, and adenovirus in the same reporting period. Our surveillance showed pediatric rates among children 14 and under were rising, prompting China’s National Institute for Communicable Disease Control to issue public advisories. The World Health Organization assessed the surge as “within the range expected for this time of year during the northern hemisphere winter,” but the outbreak generated global media attention and pushed hMPV into the public conversation in a way we had not seen before. Because hMPV has no approved vaccine and no antiviral treatment, diagnostic testing is the primary clinical tool for managing patients and controlling transmission. That reality creates a direct commercial opportunity for our valued distribution partners — our market data confirms the demand for hMPV test kits is rising, and the supply chain is still catching up. Distributors who add hMPV testing to their respiratory portfolio now — before the next winter respiratory season peaks — will be positioned to capture demand when hospitals, clinics, and pharmacies start asking for these tests. 2. What Is hMPV? A Virus Hiding in Plain Sight Since 2001 Human metapneumovirus was first discovered in 2001 in the Netherlands by Bernadette van den Hoogen and colleagues, though serological evidence suggests it has been circulating in human populations for at least 60 years. The virus belongs to the Pneumoviridae family, making it a close relative of respiratory syncytial virus (RSV). Both viruses target the respiratory tract and cause similar clinical presentations — which is precisely why hMPV has been underdiagnosed for decades. Clinicians often cannot distinguish hMPV from RSV, influenza, or even COVID-19 based on symptoms alone. The virus has two main genetic lineages — subtype A and subtype B — each with further subgroups. Virtually all children worldwide have been exposed to hMPV by age 5, according to serological studies. Reinfections are common throughout life because natural immunity wanes over time. Unlike influenza, which has a well-established surveillance infrastructure and public awareness, hMPV has operated in the shadows of respiratory diagnostics. As the CDC notes, “broader use of molecular diagnostic testing has increased identification and awareness of HMPV as a cause of upper and lower respiratory infection.” Seasonal Patterns and Geographic Spread In temperate climates, our market intelligence shows hMPV peaks during late winter through spring — overlapping with the tail end of influenza season and the RSV season. This timing means hMPV circulates precisely when healthcare systems are already burdened with respiratory cases. Because the incubation period is 3-6 days and transmission occurs through respiratory droplets and direct contact, outbreaks can accelerate rapidly in crowded settings such as schools, nursing homes, and hospital wards. 3. Clinical Impact: Who Gets Sick and How Bad The clinical significance of hMPV varies sharply by patient population, and understanding this variation is what makes the business case for distributors. Our clinical data shows the virus produces symptoms ranging from mild upper respiratory illness (cough, fever, nasal congestion) to severe lower respiratory disease including bronchiolitis, pneumonia, and COPD exacerbation. Children Under 5: The Highest-Risk Pediatric Group A US study we reference covering 2010-2012 found that hMPV was responsible for 15% of community-acquired pneumonia requiring hospitalization in children under 5 years old. In our experience working with pediatric hospital distributors across Asia and Europe, this statistic translates directly into procurement decisions: pediatric wards need hMPV in their respiratory panel, not as an afterthought but as a core diagnostic target. Older Adults Over 65: Nearly as Severe as Influenza Our elderly patient data confirms hMPV is nearly as common and severe as influenza, according to multiple epidemiological studies. Complications include pneumonia, asthma attacks, middle ear infections, and croup. For immunocompromised patients, hMPV can cause prolonged illness requiring hospitalization. Because these populations overlap heavily with the patients who already receive flu and COVID testing, adding hMPV to the diagnostic panel is a natural extension that healthcare providers are increasingly requesting. 4. Why hMPV Matters for Distributors: Market Demand Beyond Flu and COVID We see three converging forces driving demand for hMPV test kits among our distribution partners worldwide: First, post-COVID awareness. The pandemic trained both clinicians and patients to expect respiratory pathogen testing. Flu and COVID rapid tests are now commodity products. Distributors who offer only flu and COVID are leaving revenue on the table — and leaving their healthcare customers without the diagnostic breadth they need. Second, the multiplex testing trend. Because hMPV, RSV, influenza, and adenovirus circulate simultaneously and produce overlapping symptoms, clinicians increasingly prefer multiplex combo panels that detect multiple pathogens from a single sample. A patient presenting with cough and fever in January could have any of five or six respiratory viruses. A combo test that rules out all of them in 15 minutes is far more clinically useful than a single-analyte test. Third, the 2024 outbreak awareness. The China hMPV outbreak generated headlines worldwide and made “hMPV” a searchable term for the first time among non-specialist audiences. Distributors in Malaysia, Hong Kong, India, Pakistan, and the Middle East reported increased inquiry volumes for hMPV test kits during and after the outbreak. Because hMPV follows a seasonal pattern, we expect this seasonal demand to intensify further each winter respiratory season. 5. Testing hMPV: From Molecular Assays to Rapid Antigen Tests Our laboratory protocol follows CDC guidance: molecular assays (nucleic acid amplification tests) as the preferred method for hMPV diagnosis, with antigen tests as an alternative for point-of-care settings. Understanding the strengths of each approach helps distributors select the right products for their target markets. Molecular Assays: The Highest-Accuracy Method RT-qPCR delivers the highest diagnostic accuracy for hMPV detection. It offers high sensitivity, quick results (1-3 hours), quantifies viral load, and has lower contamination probability than conventional PCR. However, molecular assays require laboratory infrastructure, trained technicians, and higher per-test costs — making them practical for hospital laboratories and reference labs but impractical for point-of-care, pharmacy, or field testing. Rapid Antigen Tests: The Point-of-Care Solution For our point-of-care and decentralized testing product lines, rapid antigen tests using lateral flow immunoassay technology provide results within 15 minutes from a nasal swab. Our rapid antigen tests use colloidal gold immunochromatography to detect hMPV antigens with high sensitivity and high specificity. The tests require no instruments, no electricity, and no specialized training — making them suitable for pharmacies, clinics, emergency departments, and field deployment. We manufacture these tests under Australian TGA certification. 6. Multiplex Combo Tests: The Future of Respiratory Diagnostics Our production team has developed a range of multiplex respiratory combo panels that detect hMPV alongside other respiratory pathogens from a single nasal swab. The flagship product in this range is our TGA-approved 6-in-1 combo test that detects: Influenza A Influenza B COVID-19 (SARS-CoV-2) hMPV (Human Metapneumovirus) RSV (Respiratory Syncytial Virus) Adenovirus Because all six pathogens we test for produce overlapping respiratory symptoms — cough, fever, congestion, shortness of breath — our advanced single combo test identifies the causative agent in 15 minutes, far more efficient than running six separate single-analyte tests. Our test uses a nasal swab sample, requires no instruments, and can be performed by any trained healthcare worker at the point of care. We also manufacture a range of 3-in-1, 4-in-1, 5-in-1, and even 10-target respiratory panels that include hMPV. This range allows our distributors to offer their healthcare customers a choice between budget-friendly lower-plex panels and comprehensive higher-plex panels depending on the clinical setting and reimbursement environment. In our experience, our 6-in-1 panel is the sweet spot for most international markets — it covers the six respiratory pathogens that our clinical partners care about most while keeping the per-test cost manageable. 7. What Distributors Need to Know: Regulatory, Storage, and MOQ Regulatory Certifications We manufacture all our hMPV and combo test kits under Australian TGA certification, meeting the requirements of Australia’s Therapeutic Goods Administration. For distributors entering new markets, our dedicated regulatory team provides comprehensive documentation support for local registration submissions. Storage Conditions and Shelf Life All our rapid antigen test kits have a storage temperature range of 4-30 degrees Celsius and a shelf life of 24 months from the date of manufacture. Because the tests use lateral flow immunoassay technology with stable colloidal gold conjugates, they do not require cold chain logistics — a significant advantage for our distributors serving tropical and subtropical markets where cold chain infrastructure may be limited. We include desiccant sachets in each test kit pouch to protect against humidity during storage and transport. Minimum Order Quantities and OEM Customization Our standard minimum order quantity is 5,000 units for our catalog products. For distributors who want OEM customization — private label branding, custom packaging, custom cassette design, or multi-language instructions for use — our minimum order quantity is 50,000 units. We offer free samples for evaluation and internal validation before you commit to a production order. For first-time buyers, we recommend starting with a 5,000-unit trial order to validate market demand before scaling to larger volumes. Our production capacity allows us to fulfill orders of 100,000+ units within 2-3 weeks for standard products. 8. How Testsealabs Supports Your hMPV Test Portfolio Our Hangzhou facility spans over 56,000 square meters and houses dedicated production lines for lateral flow rapid diagnostic tests. We have been manufacturing infectious disease test kits since our founding in 2015, and our hMPV product range has grown significantly from a single standalone test to a comprehensive portfolio of standalone and multiplex panels. What sets our manufacturing approach apart is vertical integration. We control the entire production chain — from the biological raw materials (antigens and antibodies) through the finished test cassette assembly, packaging, and quality release. Because we manufacture our own high-quality critical raw materials, we can guarantee consistent lot-to-lot consistency and reduce supply chain disruption risk for our distributors. This vertical integration matters especially for hMPV tests, where antigen quality directly determines test sensitivity. For distributors evaluating our products, we offer: Free samples for evaluation and internal validation testing Technical data sheets with sensitivity and specificity performance data Regulatory documentation packages for local market registration Marketing support including product images, brochures, and training materials Dedicated account management for ongoing order coordination and technical support We invite all distributors to contact our team to request samples, discuss OEM options, or receive a quotation for hMPV standalone tests or multiplex combo panels. Our goal is to help you build a respiratory testing portfolio that meets the diagnostic needs of your healthcare customers worldwide and their patients — and captures the growing demand for hMPV testing in your market. Why act now? hMPV peaks during late winter and spring in temperate climates. Distributors who place orders in Q3 will have inventory on shelves before the respiratory season begins. Our standard production lead time is 2-3 weeks for catalog products, plus shipping time to your destination market. Our commitment to our distributors goes beyond manufacturing. We provide ongoing market intelligence, technical training, and regulatory updates to help you succeed in your local market. When you partner with us, you gain a manufacturing partner who understands the IVD industry and invests in product innovation. 9. Frequently Asked Questions What is the difference between an hMPV rapid antigen test and a molecular (PCR) test? Our rapid antigen test detects hMPV proteins (antigens) directly from a nasal swab using lateral flow immunoassay technology, delivering results within 15 minutes without instruments. Molecular tests (RT-qPCR) detect the virus’s RNA genetic material and offer higher sensitivity, but require laboratory equipment, trained technicians, and 1-3 hours per run. For point-of-care, pharmacy, and field testing, our rapid antigen tests provide a practical balance of speed, accuracy, and cost. For confirmatory diagnosis in hospital laboratories, molecular assays deliver the highest diagnostic accuracy. We recommend distributors offer both options to serve different clinical settings. Can your hMPV combo test distinguish between hMPV and RSV? Yes. Our multiplex combo panels use separate test lines for each target pathogen. Because hMPV and RSV belong to the same viral family (Pneumoviridae) and produce similar clinical symptoms, distinguishing between them is clinically important — the treatment and isolation protocols differ. Our 6-in-1 combo cassette has independent detection lines for hMPV and RSV, so a single test clearly identifies which virus is causing the patient’s respiratory illness. This differentiation is something single-analyte flu or COVID tests cannot provide. What certifications do your hMPV test kits carry? Our hMPV test kits carry Australian TGA certification, meeting the regulatory requirements of Australia’s Therapeutic Goods Administration. Our manufacturing facility also holds ISO 13485 quality management certification. For other market registrations, our experienced regulatory affairs team provides customized documentation packages tailored to your specific country’s requirements. What is the storage temperature and shelf life of your hMPV rapid tests? All our rapid antigen test kits, including standalone hMPV tests and multiplex combo panels, have a storage temperature range of 4-30 degrees Celsius and a shelf life of 24 months from the date of manufacture. Because our tests use colloidal gold immunochromatography technology with stable conjugate chemistry, they do not require cold chain logistics or refrigerated storage. Each test cassette is individually sealed in an aluminum foil pouch with a desiccant sachet to protect against humidity. This storage profile makes our tests practical for distribution in tropical climates and for pharmacies, clinics, and field settings where refrigeration may not be available. What is your minimum order quantity for hMPV test kits? Our standard minimum order quantity for catalog hMPV test kits is 5,000 units. For distributors who want OEM customization — including private label branding, custom packaging design, custom cassette colors, or multi-language instructions for use — our minimum order quantity is 50,000 units. We offer free samples for evaluation and internal validation before you commit to a production order. For first-time buyers, we recommend starting with a 5,000-unit trial order to validate market demand before scaling to larger volumes. Our production team can fulfill orders of 100,000+ units within 2-3 weeks for standard catalog products. Why should I add hMPV testing to my respiratory portfolio when flu and COVID tests already sell well? Flu and COVID rapid tests have become commodity products with compressed margins. Adding hMPV — either as a standalone test or as part of a multiplex combo panel — differentiates your product offering and captures a growing market segment that your competitors may not yet be addressing. Because hMPV has no vaccine and no antiviral treatment, diagnostic testing is the only clinical tool available for patient management. Healthcare providers increasingly request respiratory panels that cover more than just flu and COVID, especially during winter respiratory season when hMPV, RSV, and adenovirus circulate simultaneously. Our multiplex combo panels allow you to offer a comprehensive respiratory solution from a single product line, reducing your procurement complexity while expanding your clinical coverage. Angela Qin is the International Sales Director at Hangzhou Testsea Biotechnology Co., Ltd. (Testsealabs), with 10+ years of experience in the in vitro diagnostic (IVD) and veterinary product industry. Founded in 2015 with the pursuit “serving society, health world,” Testsealabs specializes in the R&D, production, and sales of rapid diagnostic products, including tests for coronavirus disease, cardiovascular diseases, inflammation, tumor markers, infectious diseases, drug abuse, and pregnancy. Leveraging proprietary platforms (immunological detection, molecular biology, protein chip, and biological raw materials), Angela helps global distributors, hospitals, public health institutions, and veterinary clients source reliable, high-quality diagnostic solutions from China — backed by strict quality control and a customer-first philosophy. Testsealabs’ products are widely used in rapid diagnosis, treatment monitoring, maternal and child healthcare, drug and alcohol testing, and have been sold to over 100 countries worldwide. Post time: Aug-14-2026
